1. Scrip
  2. >>Scrip Perspectives

10 Pivotal Studies To Look Out For In 2024

 
• By Alexandra Shimmings

While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.    

Clinical Trial
• Source: Shutterstock

Sanofi ended 2023 with a disappointment for its cancer therapy, tusamitamab ravtansine, but in 2024 eyes will turn to another investigational product, the BTK inhibitor tolebrutinib, which is due to report data from the Phase III GEMINI 1 & 2 program in relapsing multiple sclerosis and HERCULES results in secondary progressive MS around mid-2024.

The stakes have been raised by the shock setback late last year for Merck KGaA’s similar candidate, evobrutinib. (Also see...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Perspectives

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Eleanor Malone

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

M&A Takeoff May Be Delayed, Experts Predict

 
• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

10 Clinical Trials To Look Out For In 2025

 
• By Alexandra Shimmings

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.